Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Aug:229:108786.
doi: 10.1016/j.clim.2021.108786. Epub 2021 Jun 18.

Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study

Miguel García-Grimshaw  1 , Santa Elizabeth Ceballos-Liceaga  2 , Laura E Hernández-Vanegas  3 , Isaac Núñez  4 , Noé Hernández-Valdivia  2 , Daniel Amado Carrillo-García  2 , Anaclara Michel-Chávez  1 , Javier Andrés Galnares-Olalde  3 , Guillermo Carbajal-Sandoval  2 , María Del Mar Saniger-Alba  1 , Roger A Carrillo-Mezo  5 , Sergio Fragoso-Saavedra  6 , Alba Espino-Ojeda  7 , Carlos Blaisdell-Vidal  7 , Juan Luis Mosqueda-Gómez  8 , Juan Sierra-Madero  9 , Rogelio Pérez-Padilla  10 , José Luis Alomía-Zegarra  2 , Hugo López-Gatell  2 , José Luis Díaz-Ortega  11 , Gustavo Reyes-Terán  12 , Antonio Arauz  2 , Sergio Iván Valdés-Ferrer  13
Affiliations
Observational Study

Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study

Miguel García-Grimshaw et al. Clin Immunol. 2021 Aug.

Abstract

mRNA vaccines against SARS-CoV-2 are remarkably effective. Limited information exists about the incidence of adverse events following immunization (AEFI) with their use. We conducted a prospective observational study including data from 704,003 first-doses recipients; 6536 AEFI were reported, of whom 65.1% had at least one neurologic AEFI (non-serious 99.6%). Thirty-three serious events were reported; 17 (51.5%) were neurologic (observed frequency, 2.4/100,000 doses). At the time of writing this report, 16/17 cases had been discharged without deaths. Our data suggest that the BNT162b2 mRNA COVID-19 vaccine is safe; its individual and societal benefits outweigh the low percentage of serious neurologic AEFI. This information should help to dissipate hesitancy towards this new vaccine platform.

Keywords: Adverse event; BNT162b2; COVID-19; SARS-CoV-2; Vaccine.

PubMed Disclaimer

Conflict of interest statement

All authors declare no competing interests. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

    1. Johns Hopkins University, Johns Hopkins Coronavirus Resource Center 2021. https://coronavirus.jhu.edu/map.html (accessed March 29, 2021)
    1. de México Gobierno, de Salud Secretaría. Guía técnica para la aplicación de la vacuna BNT162b2 Pfizer/BioNTech contra el virus SARS-CoV-2. 2021. https://coronavirus.gob.mx/wp-content/uploads/2021/01/GuiaAplicacionVx_B... (accessed March 2, 2021)
    1. de México Gobierno. Dirección General de Epidemiología, Manual de procedimientos estandarizados para la vigilancia epidemiológica de eventos supuestamente atribuibles a la vacunación o inmunización (ESAVI) 2021. https://epidemiologia.salud.gob.mx/gobmx/salud/documentos/manuales/42_Ma... (accessed March 2, 2021)
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Marc G. Pérez, Moreira E.D., Zerbini C., Bailey R., Swanson K.A., Roychoudhury S., Koury K., Li P., Kalina W.V., Cooper D., Frenck R.W., Hammitt L.L., Türeci Ö., Nell H., Schaefer A., Ünal S., Tresnan D.B., Mather S., Dormitzer P.R., Şahin U., Jansen K.U., Gruber W.C., C4591001 Clinical Trial Group Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Gee J., Marquez P., Su J., Calvert G.M., Liu R., Myers T., Nair N., Martin S., Clark T., Markowitz L., Lindsey N., Zhang B., Licata C., Jazwa A., Sotir M., Shimabukuro T. First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021. MMWR Morb. Mortal. Wkly Rep. 2021;70:283–288. doi: 10.15585/mmwr.mm7008e3. - DOI - PMC - PubMed

Publication types